Vigabatrin

DOI

Bibliographic Information

Other Title
  • ビガバトリン

Search this article

Description

Vigabatrin（VGB, Sabril®）is a new antiepileptic drug for infantile spasms, which was approved in Japan in 2016. VGB is the first-line therapy for infantile spasms, as is ACTH. Although apparent efficacy has been reported, a significant side effect（visual field loss）has received much attention. In Japan, all patients who use VGB should receive regular ophthalmologic examination with electroretinogram. In this section, the efficacy of VGB therapy and the management of side effects are explained.

Journal

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top